Table 1.
Empirical data sets used in our simulation study
| Original study | Health intervention | Sampling frame available | Country | Number of sites |
|---|---|---|---|---|
| Avahan20 | HIV prevention | No | India | 129 |
| EPIC8, 9, 10, 11, 12, 13 | Routine immunization | Yes | Benin | 46 |
| Ghana | 50 | |||
| Honduras | 71 | |||
| Moldova | 50 | |||
| Uganda | 49 | |||
| Zambia | 51 | |||
| MATCH7 | HIV treatment | Yes | Ethiopia | 41 |
| Malawi | 30 | |||
| Rwanda | 30 | |||
| Zambia | 30 | |||
| ORPHEA19 | Prevention of mother-to-child transmission of HIV | No | Kenya | 51 |
| Rwanda | 53 | |||
| South Africa | 42 | |||
| Zambia | 56 | |||
| ORPHEA19 | HIV testing and counseling | No | Kenya | 56 |
| Rwanda | 53 | |||
| South Africa | 42 | |||
| Zambia | 60 | |||
| Marseille et al.21 | HIV treatment | No | Zambia | 45 |
EPIC indicates the multi-country study on the costing and financing of routine immunization and new vaccines; HIV, human immunodeficiency virus; MATCH, Multi-Country Analysis of Treatment Costs for HIV/AIDS; ORPHEA, Optimizing the Response in Prevention: HIV Efficiency in Africa.